Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19
Article
[키워드] 95% CI
acute respiratory distress
adverse event
all-cause mortality
Anticoagulant
appear
ARDS
association
clinical
consecutive patient
COVID-19
death
different dose
dosage
dose
doses
Enoxaparin doses
evaluated
higher risk
hospitals
In-hospital
In-hospital death
incidence
intubation
Italian
LMWH
low molecular weight
mechanical ventilation
Mortality
multivariable analysis
outcome
outcome measure
overall mortality
Patient
patients hospitalized
patients with COVID-19
primary end-point
pro-thrombotic
Prophylactic
prophylactic dose
Randomized
regimen
secondary
significantly lower
suggested
supplementary material
syndrome
Thromboprophylaxis
thrombotic event
treated
Treatment
Venous Thromboembolism
[DOI] 10.1007/s11239-021-02401-x PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s11239-021-02401-x PMC 바로가기 [Article Type] Article